T1	p 111 205	in patients with acute myeloid leukemia and myelodysplastic syndromes : a Japanese multicenter
T2	p 391 513	in patients with acute myeloid leukemia ( AML ) or myelodysplastic syndromes ( MDS ) during and after chemotherapy . There
T3	p 519 592	4 cases with possible systemic fungal infection in the itraconazole group
T4	p 734 751	patients with MDS
T5	p 1337 1365	patients with AML or MDS who
T6	i 33 79	itraconazole capsules and fluconazole capsules
T7	i 321 328	capsule
T8	i 338 351	fluconazole (
T9	i 362 380	and itraconazole (
T10	i 574 586	itraconazole
T11	i 649 660	fluconazole
T12	i 882 894	itraconazole
T13	i 913 924	fluconazole
T14	i 1152 1163	fluconazole
T15	i 1227 1239	itraconazole
T16	i 1413 1425	itraconazole
T17	i 1501 1512	fluconazole
T18	o 550 566	fungal infection
T19	o 669 683	Adverse events
T20	o 810 817	numbers
T21	o 853 863	infections
T22	o 1056 1062	counts
T23	o 1122 1144	frequency of infection
T24	o 1324 1333	tolerated